drugset
drugset / Trial / NCT07070440

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

NCT07070440 ↗

Phase 1/2 Recruiting 100 enrolled Dizal Pharmaceuticals
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.

Timeline

Start
2025-07-16
Primary completion
2027-06
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject DZD6008 Unknown 40 mg Oral
Subject DZD6008 Unknown 60 mg Oral
Subject DZD6008 Unknown 90 mg Oral
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma